tetano
Editor, Senior Moderator
Clin Infect Dis. 2013 Oct 22. [Epub ahead of print]
Administration of AS03B-adjuvanted A(H1N1)pdm09 vaccine in children under 3 years enhances antibody response to H3 and B viruses following a single dose of trivalent vaccine one year later.
Hoschler K, Andrews NJ, Faust SN, Finn A, Pollard AJ, Snape MD, Walker WT, Zambon M, Miller E.
Source
Public Health England (Colindale), London, UK.
Abstract
Background. We report a follow up clinical and serological investigation of 274 children receiving seasonal influenza vaccine (TIV) one year after receipt of either AS03B-adjuvanted subunit or whole virus monovalent A(H1N1)pdm09 vaccine and describe the antibody responses to the H3N2 A/Perth/16/2009 and B/Brisbane/60/2008 components of TIV. Method and Findings. Vaccine responses were analysed using Haemagglutination Inhibition (HAI) assays. In individuals under 3 years of age, previous receipt of adjuvanted vaccine resulted in higher HAI antibody responses to H3N2 and B strains compared to non-adjuvanted vaccine (fold change 16.8 vs 4.3 for H3N2 and 7.0 vs 1.6 for B). In older children, responses to the H3 and B components of TIV were similar between vaccine groups. Sera taken pre- and post pandemic vaccine were also analysed by HAI with A/Perth/16/2009 virus. This analysis showed that 11.1% of children receiving the AS03B-adjuvanted vaccine but only 1.4% in the non-adjuvanted group had a 4-fold rise to A/Perth/16/2009. Conculsion. AS03B-adjuvanted A(H1N1)pdm09 influenza vaccine generates a cross-reactive antibody response to H3N2 in children and enhances responses to heterologous subtypes in <3-year-old children one year later.
PMID:
24149079
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24149079
Administration of AS03B-adjuvanted A(H1N1)pdm09 vaccine in children under 3 years enhances antibody response to H3 and B viruses following a single dose of trivalent vaccine one year later.
Hoschler K, Andrews NJ, Faust SN, Finn A, Pollard AJ, Snape MD, Walker WT, Zambon M, Miller E.
Source
Public Health England (Colindale), London, UK.
Abstract
Background. We report a follow up clinical and serological investigation of 274 children receiving seasonal influenza vaccine (TIV) one year after receipt of either AS03B-adjuvanted subunit or whole virus monovalent A(H1N1)pdm09 vaccine and describe the antibody responses to the H3N2 A/Perth/16/2009 and B/Brisbane/60/2008 components of TIV. Method and Findings. Vaccine responses were analysed using Haemagglutination Inhibition (HAI) assays. In individuals under 3 years of age, previous receipt of adjuvanted vaccine resulted in higher HAI antibody responses to H3N2 and B strains compared to non-adjuvanted vaccine (fold change 16.8 vs 4.3 for H3N2 and 7.0 vs 1.6 for B). In older children, responses to the H3 and B components of TIV were similar between vaccine groups. Sera taken pre- and post pandemic vaccine were also analysed by HAI with A/Perth/16/2009 virus. This analysis showed that 11.1% of children receiving the AS03B-adjuvanted vaccine but only 1.4% in the non-adjuvanted group had a 4-fold rise to A/Perth/16/2009. Conculsion. AS03B-adjuvanted A(H1N1)pdm09 influenza vaccine generates a cross-reactive antibody response to H3N2 in children and enhances responses to heterologous subtypes in <3-year-old children one year later.
PMID:
24149079
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24149079